<DOC>
	<DOCNO>NCT01132768</DOCNO>
	<brief_summary>Effect olmesartan medoxomil ( 20-40 mg ) plaque regression hypertensive patient carotid atherosclerosis .</brief_summary>
	<brief_title>The Confirmatory Olmesartan Plaque Regression Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>Male female Caucasian outpatient age &gt; 40 year . High BP define mean SeSBP/SeDBP ≥ 140/90 mmHg . One follow additional risk factor : Smoking ; Dyslipidaemia ( highdensity lipoprotein ( HDL ) cholesterol &lt; 0.9 mmol/L lowdensity lipoprotein ( LDL ) cholesterol &gt; 2.6 mmol/L , triglycerides &gt; 1.7 mmol/L ) ; Left ventricular hypertrophy ; Cardiocerebrovascular event &gt; 6 month ago ; Presence target organ damage . Noncalcified ( mark shadow ) plaque CC artery , internal carotid artery carotid bulb PV ≥ 0.040 cm³ ( ≥ 40 µL ) accord measurement EUTARC . Secondary high grade hypertension include grade III hypertension ( SeSBP &gt; 180 mmHg SeDBP &gt; 105 mmHg ) . Stroke , myocardial infarction within previous 6 month . Interventional surgical vascular treatment within previous 3 month . Presence significant narrowing aortic bicuspid valve severe obstruction cardiac outflow ( hypertrophic cardiomyopathy ) . Symptomatic heart failure . Diabetes . Chronic obstructive pulmonary disease ( COPD ) asthma . Claudication intermittens stage II b higher . Clinical evidence severe renal disease [ include renovascular occlusive disease , nephrectomy and/or renal transplant , creatinine clearance &lt; 30 mL/min , macroalbuminuria ( &gt; 300 mg albumin/24 hour 300 µg albumin/mg creatinine ) ] . Treatment angiotensin convert enzyme ( ACE ) inhibitor angiotensinreceptor blocker ( ARBs ) last 3 month . Start treatment lipidlowering agent modification dosage within last 3 month . Electrocardiographic ( ECG ) evidence 2nd 3rd degree atrioventricular ( AV ) block , atrial fibrillation , cardiac arrhythmia ( require therapy ) bradycardia ( &lt; 50 beats/min rest ) . Known intolerance study drug . Impaired liver function test suggest severe liver disorder . Any life threaten disease . Duplex sonographically determine stenosis common internal carotid artery &gt; 75 % . Plaque mark shadow calcification . Target plaques CC artery extend internal external artery . Pregnant lactate female subject . Female subject childbearing potential without adequate contraception : intrauterine device , hormonal contraceptive , either oral , depot , patch injectable double barrier method condom diaphragms spermicidal gel foam . If female becomes pregnant trial , withdrawn immediately ( see section 9.4 ) . Subject currently enrol yet complete least 30 day since end another investigational device drug study receive investigational agent . Subject previously enter study . Subjects receive ATE within 30 day prior enter active treatment phase . Subjects unwilling unable provide inform consent participate satisfactorily entire trial period . Subjects history alcohol drug abuse . Subjects know malabsorption syndrome . Subjects donate lose 450 mL blood last three month Screening .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>